Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606258 | 0.94 | P2RX7 (0.45) | CTSLCTSBCTSSP2RX7SYK | |
| SCHEMBL3205700 | 0.92 | CTSS (0.47) | CTSLCTSBCTSSP2RX7SYK | |
| SCHEMBL24094564 | 0.91 | CTSB (0.42) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL21009793 | 0.89 | MEN1 (0.46) | CTSLCTSBCTSSP2RX7MEN1 | |
| SCHEMBL22981749 | 0.87 | CTSL (0.43) | CTSLCTSBCTSSSYKMEN1 | |
| SCHEMBL2797417 | 0.86 | MEN1 (0.46) | CTSLCTSBCTSSP2RX7MEN1 | |
| SCHEMBL2206561 | 0.86 | MEN1 (0.47) | CTSLCTSBCTSSP2RX7MEN1 | |
| SCHEMBL25597457 | 0.85 | BACE1 (0.43) | CTSLCTSBCTSSP2RX7MEN1 | |
| SCHEMBL23121261 | 0.84 | HTT (0.44) | CTSLCTSBCTSSSYKMEN1 | |
| SCHEMBL4569995 | 0.84 | CTSS (0.51) | CTSLCTSBCTSSP2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4161927-B9 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4161927-B1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4161927-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | CTSL 2022/4885CTSB 3750/4885CTSS 3033/4885 |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC5R | CTSL 3119/4885CTSB 3196/4885CTSS 3958/4885 |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | CTSL 3726/4885CTSB 2484/4885CTSS 3641/4885 |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | MC4R, MC3R, MC5R | CTSL 3119/4885CTSB 3196/4885CTSS 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.